![](https://news.europawire.eu/wp-content/uploads/2024/03/EQT-Life-Sciences-Portfolio-Company-Amolyt-Pharma-Acquired-by-Alexion-AstraZeneca-Rare-Diseases-for-1.05-Billion-144x144.jpg)
(IN BRIEF) EQT Life Sciences announces the acquisition of its portfolio company, Amolyt Pharma, by Alexion, AstraZeneca Rare Diseases, for a total deal value of $1.05 billion. This acquisition underscores Amolyt’s significant advancements in developing novel treatments for rare endocrine … Read the full press release